Literature summary for 2.4.2.31 extracted from

Liu, J.H.; Yang, J.Y.; Hsu, D.W.; Lai, Y.H.; Li, Y.P.; Tsai, Y.R.; Hou, M.H.
Crystal structure-based exploration of arginine-containing peptide binding in the ADP-ribosyltransferase domain of the type III effector XopAI protein (2019), Int. J. Mol. Sci., 20, 5085 .

Search for more literature for 2.4.2.31

Cloned(Commentary)

Cloned (Comment)	Organism
expressed in Escherichia coli BL21(DE3)RIL cells	Xanthomonas citri pv. citri

Crystallization (Commentary)

Crystallization (Comment)	Organism
hanging drop vapor diffusion method, using either 15% (w/v) PEG 400, 5.5% (w/v) PEG 20000, and 50 mM KH2PO4, pH 8.0 or 16.5% (w/v) PEG 400, 6.5% (w/v) PEG 20000, and 50 mM KH2PO4, pH 8.0	Xanthomonas citri pv. citri

Natural Substrates/ Products (Substrates)

Natural Substrates	Organism	Comment (Nat. Sub.)	Natural Products	Comment (Nat. Pro.)	Rev.	Reac.
NAD+ + protein L-arginine	Xanthomonas citri pv. citri	-	nicotinamide + Nomega-(ADP-D-ribosyl)-protein-L-arginine	-	?
NAD+ + protein L-arginine	Xanthomonas citri pv. citri XW19	-	nicotinamide + Nomega-(ADP-D-ribosyl)-protein-L-arginine	-	?

Organism

Organism	UniProt	Comment	Textmining
Xanthomonas citri pv. citri	A0A0U5GCU5	-	-
Xanthomonas citri pv. citri XW19	A0A0U5GCU5	-	-

Purification (Commentary)

Purification (Comment)	Organism
Ni-NTA column chromatography	Xanthomonas citri pv. citri

Substrates and Products (Substrate)

Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
NAD+ + protein L-arginine	-	Xanthomonas citri pv. citri	nicotinamide + Nomega-(ADP-D-ribosyl)-protein-L-arginine	-	?
NAD+ + protein L-arginine	-	Xanthomonas citri pv. citri XW19	nicotinamide + Nomega-(ADP-D-ribosyl)-protein-L-arginine	-	?

Synonyms

Synonyms	Comment	Organism
arginine-specific mono-ADP-ribosyltransferase	-	Xanthomonas citri pv. citri
ART	-	Xanthomonas citri pv. citri
XAC3230	-	Xanthomonas citri pv. citri
XopAI	-	Xanthomonas citri pv. citri

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)